A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Trial details
- Registry ID
- NCT06111235
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235 | CGON | Phase 3 | Active not recruiting | 2026-11Estimated |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461 | CGON | Phase 2 | Completed | 2023-03-07Actual |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinNCT04452591 | CGON | Phase 3 | Active not recruiting | 2030-06-16Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |